ACTRN12621000975897已完成1 期
A Phase 1, randomized study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ONC201 and the effects of food on the bioavailability of ONC201 following oral administration in healthy adult subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions in this protocol.
- •2. Male or female between 18 to 55 years of age.
- •3. Female must be of non-childbearing potential i.e., postmenopausal woman or a premenopausal woman documented as surgically sterile following either a hysterectomy and/or bilateral oophorectomy, tubal ligation or placement of bilateral fallopian tube occlusion, or with medically documented ovarian failure.
- •4. Males must be surgically sterilized OR must agree to use an acceptable method(s) of contraception during heterosexual intercourse with a female partner capable of becoming pregnant while enrolled in the study
- •5. Males must agree to refrain from sperm donation during the study and for at least 90 days after study drug administration.
- •6. Body mass index from 18 to 32 kg/m2, inclusive.
- •7. Participants who are overtly healthy as determined by medical evaluation and judgment of the investigator including medical history, Physical Exam, laboratory tests, vital signs, and cardiac monitoring.
排除标准
- •1.If male, have a female partner who is pregnant or planning to become pregnant during the study or within 90 days after study drug administration.
- •2.Have received any investigational drug, agent, or device within 30 days prior to Day 1, or current participation in another investigational study.
- •3. Have a positive result for Hepatitis B/C or HIV.
- •4. Have a positive test for drugs of abuse, cotinine, and/or alcohol
- •5. Current history of heavy tobacco/nicotine use.
- •6. Any serious or active medical or psychiatric illness, which could interfere with participant treatment, assessment, or compliance with the protocol.
- •7. Have a history of a gastrointestinal condition that could interfere with the absorption of the study drug
- •8. Have a history or symptoms of cardiovascular disease, including but not limited to coronary artery disease, hypertension, congestive heart disease.
- •9. Have a history of hematological disorders, including disorders such as a bleeding disorder or a risk of gastrointestinal bleeding.
- •10. Have a history of chronic liver disease or hepatic impairment,
- •11. Total bilirubin greater than the upper limit of the normal reference range at screening or on Period 1 Day -1.
- •12. Have symptoms of acute infection within 2 weeks prior to Period 1 Day 1.
- •13. Have clinically significant abnormal hemoglobin as determined by the investigator at the screening evaluation
- •14. Have donated a unit of blood or had clinically significant blood loss within 30 days prior to Period 1 Day 1 or donated plasma within 7 days prior to Period 1 Day 1.
- •15. Have received any prescription medication, vaccines, or any nonprescription medication (including vitamins and herbal products) within 14 days prior to Period 1 Day 1,
研究者
相似试验
已完成
1 期
Investigating the safety and tolerability of ONC201 in healthy adults - Part ACancerACTRN12621001002875Chimerix, Inc.15
已完成
1 期
Investigating the safety and tolerability of ONC201 in healthy adults under fasting and fed conditions - Part 2bCancerACTRN12621001003864Chimerix, Inc.30
招募中
不适用
Phase I/II study to evaluate the safety and immunogenicity of MG1109 in healthy adult volunteersDiseases of th respiratory systemKCT0000119Koera University Guro Hospital346
已完成
1 期
A clinical trial to test the safety of a herbal drug.CTRI/2017/11/010352SK Biolabs100
已完成
1 期
A clinical trial to test the safety of a herbal drug.CTRI/2017/10/010237SK Biolabs100